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Abstract 
Background: Gene expression changes induced by carcinogens may identify 
differences in molecular function between target and non-target organs. Target organs 
for benzo[a]pyrene (BaP) carcinogenicity in mice (lung, spleen and forestomach) and 
three non-target organs (liver, colon and glandular stomach) were investigated for 
DNA adducts by 32P-postlabelling, for gene expression changes by cDNA microarray 
and for miRNA expression changes by miRNA microarray after exposure of animals 
to BaP. Results: BaP-DNA adduct formation occurred in all six organs at levels that 
did not distinguish between target and non-target. cDNA microarray analysis showed 
a variety of genes modulated significantly by BaP in the six organs and the overall 
gene expression patterns were tissue specific. Gene ontology analysis also revealed 
that BaP-induced bioactivities were tissue specific; eight genes (Tubb5, Fos, Cdh1, 
Cyp1a1, Apc, Myc, Ctnnb1 and Cav) showed significant expression difference 
between three target and three non-target organs. Additionally, several gene 
expression changes, such as in Trp53 activation and Stat3 activity suggested some 
similarities in molecular mechanisms in two target organs (lung and spleen), which 
were not found in the other four organs. Changes in miRNA expression were 
generally tissue specific, involving, in total, 21/54 miRNAs significantly up- or down-
regulated. Conclusions: Altogether, these findings showed that DNA adduct levels 
and early gene expression changes did not fully distinguish target from non-target 
organs. However, mechanisms related to early changes in p53, Stat3 and Wnt/β-
catenin pathways may play roles in defining BaP organotropism. 
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Background 
DNA adduct formation is an early critical event in the process of carcinogenesis by 
which many chemical carcinogens exert their biological effects. With few exceptions, 
however, carcinogens form DNA adducts in many tissues, leading to the view that 
adducts are necessary, but not sufficient, for carcinogenesis. Thus, although there are 
linear relationships between dose, adduct levels in target organs and tumour incidence 
[1], it may be difficult to identify which organs are targets for carcinogenicity by an 
agent purely from a consideration of the levels and persistence of DNA damage. 
Several studies using transgenic mice demonstrate that there is also a lack of 
correlation between carcinogen-induced increases in mutation frequency and target 
organ specificity [2-4]. These findings suggest the importance of events subsequent to 
DNA damage and mutation in determining organotropism and inter-species 
differences of carcinogens. 
 
There have been reports of early gene expression changes in animal tissues following 
exposure to carcinogens or toxins, but thus far most studies have been limited to 
examinations of one target tissue with, usually, one non-target tissue [5-9]. No study has 
yet attempted to compare several target and non-target tissues in order to define the 
critical events subsequent to DNA damage and mutation that may determine carcinogen 
organotropism.  
 
In the present study we have tested the hypothesis that carcinogen-induced changes in 
gene expression or miRNA expression may distinguish target organs from non-target 
ones. Balb/c mice were treated with multiple carcinogenic doses of benzo[a]pyrene 
(BaP), after which DNA adduct levels and gene and miRNA expression changes were 
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measured in three target organs (lung, spleen and forestomach) and three non-target 
organs (liver, colon and glandular stomach). We found some similar expression changes 
in at least some of the target organs, but that the majority of the early gene expression 
changes were tissue specific, as were some of the biological processes related to the 
modulated genes. Nevertheless, the results shed new light on the complexity of the 
mechanism of BaP carcinogenicity and identify some responses that may determine the 
carcinogen’s organotropism. 
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Results 
DNA adducts 
32P-Postlabelling analysis of DNA from all six organs of BaP-treated mice 
(Experiment 1) showed a single adduct spot on TLC (Figure 1A). The radioactivity in 
this spot co-chromatographed with that produced by the standard benzo[a]pyrene 
diol-epoxide (BPDE)-modified DNA [10]. TLC plates of DNA from control animals 
were devoid of adducts (Figure 1A). Adduct levels in the six organs are shown in 
Figure 1B. For each organ, levels were not significantly different between males and 
females (Student’s t-test, p > 0.05). They were higher in mice treated with ten daily 
doses than in those treated with five: 50% higher in lung, 65% higher in spleen, 138% 
higher in forestomach, 41% higher in liver, 177% higher in colon and 80% higher in 
glandular stomach. The increases from five to ten doses were significant (p < 0.05) for 
all organs except lung. Differences in DNA adduct levels among the organs (1-way 
ANOVA) or between pairs of target and non-target organs (Tukey-Kramer test) were 
not significant (p > 0.05). Thus there was no significant distinction between target and 
non-target organs for DNA adduct formation. 
 
Gene expression profiles 
By comparing pooled expression profiles from all BaP-treated samples from 
Experiment 2 (males and females at 3 different BaP doses) with corn oil-treated 
controls for each organ, we identified 791 genes in lung, 956 in spleen, 535 in 
forestomach, 309 in liver, 357 in colon and 939 in glandular stomach as significantly 
modulated by BaP (Welch’s t-test, p < 0.05), combining to a total of 2741 genes 
(Supplementary Table 1). This gene list was used for the subsequent cluster and 
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functional analyses. Expression profiles were pooled in order to increase the power of 
the test and to reduce the weight of any one sample reducing the effect of outliers. 
 
Principal component analysis (PCA) and hierarchical cluster analysis (HCA)  
PCA was used to analyse the expression profile of genes modulated significantly by 
BaP in at least one organ (2741 unique genes). Separate or nearly separate clusters 
were observed for lung, spleen and liver (Figure 2A). In contrast, there was overlap 
for the conditions in forestomach, colon and glandular stomach. The expression 
profiles of modulated genes uniquely define two of the target organs, lung and spleen. 
It is clear that the variations due to tissue differences are greater than variations due to 
BaP treatment. 
 
In hierarchical clustering, the six profiles (3 doses × 2 genders) for each organ 
clustered together (Figure 2B). There was a closer similarity between the expression 
patterns of forestomach (target) and glandular stomach (non-target) than between any 
of the other organs. Again, the target organs lung and spleen clustered separately from 
the other organs. The corn-oil control samples clustered with the BaP-treated samples 
from the same organ again indicating that differences in expression profiles between 
organs were greater that the change induced by BaP.  
 
BaP-modulated gene expression in individual conditions 
We identified 958 genes in lung, 1085 in spleen, 645 in forestomach, 523 in liver, 406 
in colon and 1104 in glandular stomach that were significantly differentially 
modulated between at least one of the six conditions (3 doses × 2 genders) and corn 
oil-treated control samples (Welch’s t-test; p < 0.05). This represented 2770 different 
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genes in total, of which 1906 genes are also among the 2741 genes identified by the 
pooling profiles method. To identify a consistent response we also considered genes 
significantly altered in at least three out of six conditions, for each tissue. There were 
85 in lung, 108 in spleen, 97 in forestomach, 34 in liver, 25 in colon and 128 in 
glandular stomach (Representative genes are shown in Table 1; see Supplementary 
Table 2 for the full list). Using these criteria, only one gene Hspa8 was found to be 
up-regulated in all six organs. Hba-a1 was down-regulated in five organs. 
 
The dose and gender effects on gene expression were investigated with 2-way 
ANOVA for each of the six organs. We did not find any clear dose- or gender-
dependent expression in any of the organs. 
 
Target versus non-target gene comparisons 
When comparing the genes modulated by BaP at three or more exposure conditions, 
no gene was significantly modulated in all target organs but not in any non-target 
organ, or vice versa. Actb, Pdia3, Rpl18, Rps5 and Tmed5 were identified to be up-
regulated by BaP in comparison with corn oil-treated controls in two out of three 
target organs and in none of the non-target organs, whilst three genes were found to 
be down-regulated (Giyd2, Hbb-y, Pip5k1c). Rpl17 was found to be up-regulated in 
two out of three non-target organs and in none of the target organs. Tubb5 was found 
to be down-regulated in spleen and forestomach (two target organs) and up-regulated 
in the colon (one of the non-target organs).  
 
Examining the results of the differential analysis performed on samples pooled by 
organ it was found that 25 probes had a significant modulation caused by BaP in the 
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same direction for either all target organs or all non-target organs (Table 2; Welch’s t-
test, p < 0.05). Of these, genes Actg1, Crk and Dnajc3, and clones H3098D07 and 
H3068A11 were found to be up-regulated in all target organs and down-regulated or 
not modulated in all non-target organs. Psmd2 was down-regulated in target organs 
only and Pfpl was up-regulated in non-target organs only. Sdccag1 was up-regulated 
in all organs and Hspa5 in five organs. Hbb-y and Hba-a1 were generally down-
regulated in all organs. 
 
Functional analysis of the modulated genes  
We applied various bioinformatics approaches using the BaP-induced genes (see 
Supplementary Table 1) to identify which biological activities are modulated in BaP 
tumourigenesis. Firstly, in gene ontology (GO) analysis, the comparison of biological 
processes revealed considerable variation between the six organs (Supplementary 
Table 3). A few biological processes were common to all organs, and most of these 
were related to basic physiological activities like metabolic (GO:0008152), 
biosynthetic (GO:0009058) and macromolecule biosynthetic (GO:0009059) 
processes. Conversely, a number of processes showed tissue specificity, especially 
some cancer-associated processes, for example, response to oxidative stress in lung 
(six associated genes: Dhcr24, Gpx3, Sod1, H47, Mtf1 and Prdx6) and cell growth in 
glandular stomach (11 genes: Ube2e3, Alox12, Bcar1, Lepre1, Socs7, Sfn, Shc1, Esr1, 
Ppp2ca, Crim1 and Yeats4). Comparisons between organs suggested that processes 
including translational initiation (GO:0006413), polyamine metabolic process 
(GO:0006595), protein-RNA complex assembly (GO:0022618) and regulation of 
protein metabolic process (GO:0051246) represented target organ-specific functions 
while gas transport (GO:0015669) was the only process common to all the non-target 
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organs. As we were assessing the effects of BaP treatment we also examined 
functions known to be involved in response to other external stimuli, such as response 
to stress (GO:0006950), to DNA damage stimulus (GO:0006974) and to oxidative 
stress (GO:0006979). We found that these appeared to be different in different organs, 
but do not fully distinguish target from non-target organs (although most do occur in 
two target organs). Other interesting activities such as DNA packaging 
(GO:0006323), apoptosis (GO:0006915) and cell proliferation (GO:0008283) were 
connected to cell cycle regulatory activities. Interestingly, these biological processes 
are also mainly altered in two target organs (e.g. cell cycle and cell proliferation). 
 
Secondly, approximately half of the BaP-modulated genes in each organ were 
associated with regulatory or metabolic pathways. Over 90% of the pathways were 
found in more than one organ but most were common to two or three organs only. A 
few pathways, including cell cycle (genes including Cdkn2A, Ccng1, Pcna), MAPK 
signalling, Wnt signalling (e.g. Apc, Src, Ccnd2, Cdh1) and Jak-SAT signalling 
(Stat3), were modulated in all six organs (Supplementary Table 4), although different 
genes were found to be modulated in each case. For example, only Ccnd2 expression 
in the Wnt signalling pathway was altered in all six organs. No pathway activated by 
BaP distinguished all three target organs from all three non-target organs.  
 
Thirdly, the interactive relationships among BaP-modulated genes in each organ were 
investigated by gene association network analysis using Ingenuity Pathway Analysis 
(IPA). Over 50% of the significantly modulated genes were present in networks. 
Networks commonly have one or more core (or ‘hub’) gene that links to many others 
within the network. NFκb in network 3 of lung (Figure 3), for example, can be 
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regulated by 10 genes (Ecsit, Gpam, Ddost, Cops3, Birc4, Otud7b, Nedd4, Ube2, Btrc 
and Rnf7) and it may regulate three others (Fuca1, Cyb5r3 and Ccnd2). Other core 
genes including Erbb2, Ctnnb1, Fos, Myc, Trp53, TNF, Stat3, H-ras, Hspa8 and 
Mapk are associated with networks that had significantly modulated genes. Of these, 
Fos and Hspa8 were themselves modulated. We did not find any network functions 
that distinguished the target from the non-target organs. Instead, cancer, cell cycle, 
protein synthesis and post-translation modification were network functions common 
to all six organs.  
Taqman gene expression validation 
The expression of 21 genes was measured by real-time PCR (RT-PCR). These were 
selected because they were differentially modulated by BaP between target and non-
target organs, differentially modulated in most organs, core network genes or part of 
important pathways found to be modulated in the functional analyses. Ephx1 [11, 12], 
Cyp1a1 [13, 14] and Trp53 [15] were chosen as they have previously been 
highlighted as important in BaP modulation. Table 3 shows the expression changes of 
these 21 genes, of which 11 genes modulated by BaP represent transcriptional 
differences between target organs and non-target organs Trp53 and Pcna were down-
regulated in two target organs (lung and spleen); Cdh1, Ctnnb1 and Apc were down-
regulated in non-target organs (Ctnnb1 and Apc in colon and glandular stomach, Cdh1 
in all three non-target organs); and Src was up-regulated in two target organs (lung 
and spleen) (Table 3; Full results in Supplementary Table 5). Additionally, Ccng1, 
Ephx1, Cyp1a1, Stat3 and Hspa8 were consistently up-regulated in the six organs. 
Looking at differences in expression between BaP-treated and control mice as a ratio 
and pooling according to target status, we found eight genes (Tubb5, Fos, Cdh1, 
Cyp1a1, Apc, Myc, Ctnnb1 and Cav) to be modulated significantly differently 
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between target and non-target tissue (p < 0.05; Figure 4). Even for these genes, a 
tissue might be more consistent with the opposite group rather than with its own. For 
example, for the top hit Tubb5, the gene with the most significant difference, 
forestomach seems to be more consistent with the non-target tissues. 
 
MicroRNA (miRNA) expression 
The expressions of 54 mouse miRNAs on the microarray were first analysed using 
hierarchical cluster analysis (Figure 5). The majority of changes of miRNA 
expressions pattern were distinct for each of the six organs and the target organs did 
not cluster separately from the non-target organs. Instead, the results indicate that the 
profiles of BaP-induced miRNA expression changes in the six mouse organs are 
tissue specific.  
 
The relative miRNA expression values of the BaP-treated compared to control mice 
revealed the degree of modulation of miRNAs expression by BaP. With a cut-off of 
1.5-fold, 41 out of 54 miRNAs displayed up-regulation or down-regulation in one or 
more organ (Supplementary Table 6). For instance, mmu-miR-290 was up-regulated 
in all organs except forestomach; mmu-miR-465 was down-regulated in lung, spleen 
and glandular stomach. Twenty one significantly deregulated miRNAs were identified 
in BaP-treated samples compared with control (p < 0.05, Student’s t-test; Table 4). 
The number of miRNAs significantly altered in individual organs was as follows: 7 up, 
3 down in lung; 9 up, 1 down in spleen; 7 up, 5 down in forestomach; 8 up, 4 down in 
liver; 8 up, 0 down in colon; and 9 up, 0 down in glandular stomach (Table 4). These 
analyses did not identify any miRNA expression changes that were target organ-
specific or non-target organ-specific. 
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Discussion 
BaP is a well-studied multi-organ and multi-species genotoxic carcinogen. Its 
carcinogenic potency and organotropism in mice depends both on the route of 
administration and on the dose [3, 16-19]. Hakura et al. [3] treated mice with 125 
mg/kg b.wt/day of BaP by oral gavage for five consecutive days, which induced 
tumours in the forestomach, spleen and lung. In the present study, we treated Balb/c 
mice with BaP according to the same protocol. In addition, we administered this daily 
dose for a longer period (10 doses) in order to look for temporal changes in DNA 
adduct levels and gene expression. We also used 2- and 3-fold higher doses to 
investigate dose-related effects on gene expression. Forestomach, spleen and lung, the 
three target organs, were examined and we chose liver, colon and glandular stomach 
as non-target organs for comparison. 
 
DNA adduct formation 
As expected, BaP induced the same DNA adduct pattern, consistent with metabolic 
activation to the 7,8-dihydrodiol 9,10-epoxide and covalent binding to the N2 position 
of guanine [20], in all organs examined. The similar levels of binding in males and 
females is consistent with the carcinogenic equipotency of BaP in both sexes, but the 
order of DNA adduct formation – spleen ≥ liver > lung > glandular stomach ≥ colon > 
forestomach – did not correlate with the susceptibility of the organs to BaP 
carcinogenicity [3].  
 
Previous research has shown that mutation frequency in organs of BaP-treated mice 
was in the order of colon > forestomach > spleen > glandular stomach > liver = lung, 
while tumour incidence was in the order forestomach > spleen > lung after treating 
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male MutaMouse with 125 mg/kg b.wt/day of BaP for 5 days by oral gavage [2, 21]. 
There are other examples of a lack of correlation between DNA adducts, mutation 
frequency and tumour incidence in different organs of carcinogen-treated mice [22, 
23], although some level of correlation between mutation frequency and target organs 
[24-27], or between adduct levels and target organs [28], has been observed in some 
rodent studies.  
 
While DNA adduct formation and mutation induction are important initiating events 
in carcinogenesis, these findings point to the possible role of subsequent events in 
determining the organotropism of chemical carcinogens. Thus in the present study we 
analysed microarray expression data from six organs of mice treated with BaP to look 
for tissue-specific changes. In total, data were collected from 144 hybridisations.  
 
Tissue-specific gene expression profiles 
The analysis of the data from individual conditions (dose and gender) by PCA and by 
HCA showed that all datasets from a single organ usually grouped together.  
 
Specificity of gene expression changes induced in tissues or cell lines has been 
reported previously. For example, brain, lung, liver and spleen each displayed a 
unique altered transcriptional signature in responding to infection [29]. Organ-specific 
gene expression profiles were found in C57BL/6 mice after low dose radiation, with 
the genes altered in spleen especially different from other organs [30]. We found that 
patterns from spleen and lung (target organs) were the most distinct. In human studies, 
Shyamsundar et al. [31] found tissue-specific expression patterns when comparing 35 
human tumour tissues to their normal tissues. Other evidence for human tumour tissue 
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gene expression specificity includes data presented for brain, breast, colon, 
endometrium, kidney, liver, lung, ovary, prostate, skin and thyroid cancers [32-34].  
 
Target organs versus non-target organs 
Variations in the genes induced in target and non-target organs after carcinogen 
exposures have been reported, between kidney (target) and liver (non-target) 
following treatment of rats and mice with aristolochic acid [5, 9] or of rats with 
ochratoxin A [6], and between lung (target) and liver (non-target) of mice treated with 
BaP [7]. However, because only a single target and non-target organ were examined 
in these studies, it is possible that differences in the genes induced in the two tissues 
may represent organ-specific changes unrelated to carcinogenesis. The current study 
has addressed this limitation by comparing three target and three non-target organs. 
 
Hundred of genes were significantly modulated by BaP in each organ and the PCA 
results revealed that the overall gene expression profile in the target organ group 
differed from those regulated in the non-target organ group. Interestingly, two target 
organs (lung and spleen) presented strong variations from the three non-target organs 
while another target organ, forestomach, was closer to the non-target organs. HCA 
confirmed this result. This finding is very close to another PCA result based on the 
expression data using oligonucleotide microarrays to capture splicing information of 
22 mouse tissues [35], which showed clearly that the lung and spleen profiles were 
distinct from those of liver, colon and stomach. Additionally, Taqman results 
confirmed that several genes were modulated by BaP in a very similar pattern in lung 
and spleen, but different from the other four organs. p53 signalling pathway genes 
Trp53 and Pcna were down-regulated, oncogene Src was up-regulated. Tnfα and Nfκb 
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were down-regulated in lung and not changed in spleen. Trp53 is one of the most 
studied tumour suppressor genes because its mutation or function loss has been 
reported in many human and animal cancers [36-38]. Recently a subset of genes were 
identified to show significantly different expression in p53 wild-type (WT) cells 
relative to p53-null cells after BPDE exposure in human colon carcinoma cells 
(HCT116), and the loss of this tumour suppressor influenced the metabolic activation 
of BaP [39]. 
 
However, forestomach (target) has an overall profile similar to that of the non-target 
organs, glandular stomach and colon. One possible reason is that the crucial gene 
expression changes in forestomach were very few constituting a low percentage of the 
total variances, for example, single gene deletion in forestomach tumourigenesis such 
as Wwox [40] and c-H-Ras [41]. Another possible reason is that the overall cell types 
between forestomach and glandular stomach are similar and the variations due to BaP 
treatment were not greater than the variations due to cell similarity. 
 
Of the eight genes that were modulated significantly differently between target and 
non-target tissues (Figure 4), two are oncogenes (Fos and Myc) and three are involved 
in Wnt/β-catenin signalling (Cdh1 – cadherin 1; Ctnnb1 – catenin; Apc – 
adenomatous polyposis coli). Cyp1a1 encodes the isoform of cytochrome P450 (CYP) 
that is principally responsible for BaP metabolism. Tubb5 encodes class V Beta-
tubulin, overexpression of which in mammalian cells disrupts microtubule 
organisation and spindle assembly, and blocks cell proliferation [42]. Cav encodes 
caveolae protein 1 (caveolin), a scaffolding protein that links integrin subunits to the 
tyrosine kinase FYN; it is a tumour suppressor gene candidate and a negative 
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regulator of the Ras-p42/44 mitogen-activated kinase cascade. It can also facilitate the 
transit of Tyr-phosphorylated Stat3 into the nucleus [43] and integrin-mediated 
activation of PI3-K/Akt [44]. The over-expression of caveolin has been suggested as a 
biomarker in some human cancers [45, 46]. There is also evidence for the interaction 
of STAT3 with caveolin and HSP90 in plasma membrane raft and cytosolic complex 
[43]. Genes including Heat shock protein (Hsp) 70kD (Hspc8, Hspa5) and Hsp 90kD 
(Hspca) interact with Stat3 by binding to each other and positively activating each 
other; caveolin can assist in the binding procedure. 
 
In non-target organs, Wnt/β-catenin signalling genes Cdh1, Ctnnb1 and Apc were 
down-regulated in colon and glandular stomach. Cdh1 was also down-regulated in 
liver and was the only gene that shows mRNA changes in all three non-target organs. 
E-cadherin is associated with invasion and metastasis of human cancers [47, 48] and 
can be regulated by the Wnt pathway. In unstimulated cells most β-catenin is 
associated with E-cadherin and α-catenin at the cell surface where it helps to mediate 
cell adhesion [49]. The Wnt/β-catenin signalling pathway can be regulated during 
carcinogenesis leading accumulation of β-catenin in the nucleus. This result is 
difficult to interpret in the context of carcinogenesis. The lack of change in expression 
of Cdh1 in target organs would allow regulation to continue normally. However, since 
cell adhesion is decreased during carcinogenesis such down-regulation should not 
matter. But the story may not be this simple, because abnormal accumulation of β-
catenin in both the cytoplasm and nuclei has been reported in during cancer 
development [50-53].  
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Although consistently up-regulated in five organs (not lung), Stat3 was the only gene 
that exhibited a trend in dose-dependent changes in expression levels in the Taqman 
study based on RT-PCR analysis (Table 3). Dose-dependent changes in expression 
were observed in almost all exposure conditions in the organs. Stat3 is a member of a 
family of six different transcription factors that are closely linked with 
tumourigenesis. Activated Stat3 has been shown to protect tumour cells from 
apoptosis and promote cell proliferation by regulating genes coding anti-apoptotic and 
proliferation-associated proteins such as Bcl, Ccnd1 and c-Myc [54, 55]. Growing 
evidence suggests that Stat3 functions as an oncogene and plays a critical role in 
transformation and tumour progression. Stat3 may be activated by many growth 
factors and oncogenic kinases. These growth factors include EGF, TGF-α, IL-6 and 
hepatocyte growth factors. Oncogenic kinases include Janus kinase family (JAK) and 
Src [56]. Other reported factors include Cox2 [57], Erbb2 [58], JAKs & MAPK 
signalling [59, 60] and Itgb4 [61]. Erbb2, Itgb4 and Src were differentially expressed 
in the 6 organs in this study. 
 
Functional analyses 
cDNA microarray experiments identified hundreds of BaP-modulated genes in each 
of the six organs, and the potential significance of BaP-induced genes was 
investigated by the analyses of their involvement in particular biological processes, in 
regulatory or metabolic signalling pathways and in gene association networks.  
 
GO analyses were consistent with the hypothesis that organs share some basic 
responses to BaP [62, 63]. Thus genes involved in basic physiological activities 
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including cellular macromolecule metabolism and cellular physiological process were 
modulated in most or all organs.  
 
Comparing the biological processes between target and non-target organs, it was 
found that very few changes were common in the target or in the non-target organs, 
examples being translation initiation and protein-RNA complex assembly. These 
processes may warrant further functional investigation, as many eukaryotic translation 
initiation factors were significantly modulated by BaP in lung (Eif4g2, Eif3c, Eif4g3, 
Eif5 Mtif2 and Eif1), in spleen (Eif5a, Eif5, Eif4g2, Eif4e and Eif1) and in 
forestomach (Eif3h, Eif5, Eif4e2, Mtif2 and Eif4e). 
 
Processes identified mainly in target but also in non-target organs are those associated 
with cell cycle activity and cellular growth; or the response to external stimulus 
involving response to stress, response to heat and response to abiotic stimulus. 
Although these processes were mainly modulated in two target organs or in two non-
target organs, individual cell cycle activities and responses to external stimulus are 
potential candidate categories for functions that might discern target organs from non-
target organs. Under conditions of stress such as DNA damage, cell cycle controls 
many genes to carry out functions including DNA repair and apoptosis that repair the 
aberrant cells or cause cell death [64]. Carcinogens may induce tumourigenesis partly 
by mediating cell cycle malfunction. For instance, in MCF-7 cells BaP induces over-
expression of many cell cycle genes including TP53 and CDKN1A [39]; arsenate 
induces thymus atrophy mediated by cell cycle arrest by down-regulating E2F and 
related genes [65]; 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) makes cell cycle 
changes in murine fetal liver [66] and Rb loss abrogates cell cycle control and genome 
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integrity to promote liver tumourigenesis [67]. The observation that many cell cycle 
genes are modulated significantly by BaP in two or more target organs indicates that 
processes such as DNA replication, cell cycle checkpoint and apoptosis may be 
activated to allow repair or elimination of damaged cells. 
 
The biological processes response to stress (GO:0006950) and response to DNA 
damage stimulus (GO:0006974) were mainly found in the target organs. These 
processes are known to be linked to immune response [64] and it is well established 
that BaP modulates immune response; it suppresses the plaque-forming cell (PFC) 
response in adult male deer mice (Peromyscus maniculatus) [68]; it can accumulate 
the IgE antibody in serum and IL-4, IL-10, IL-12p70 and IFN-γ secreted by spleen 
cells in mice [69]; and it has been found be an immune suppressor at high doses, but 
an enhancer at low doses [70].  
 
Over 90% of all pathways appeared in two or three organs and many of the individual 
pathways could potentially be linked to BaP carcinogenesis. It is also possible that 
pathways common to all or most organs are linked to tumourigenesis. MAPK 
signalling, for instance, is linked to BaP carcinogenicity: BaP may induce cell cycle 
arrest through activation of ERK/Cyclin D1 signalling [71]; BaP perturbs ERK/P38 
pathway, which causes a decrease in stability and phosphorylation of p53 and down-
regulation of NFκb activation [72]; and BaP activates MAPK signalling in mouse cl41 
cells [73], in RAW 126.7 cells [74] and in A/J mice lung tumourigenesis [75]. 
Interestingly, the individual genes involved in MAPK signalling showed a strongly 
tissue-specific profile except for a very few common genes like Hspa8.  
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The Wnt signalling pathway was also commonly activated by BaP in all organs. The 
genes, including Ccnd2, Csnk1a1, Ppp2r1a, Rock1, Cul1 and Camk2b, were variably 
modulated. In another study BaP caused LEF1 NH(2)-terminal mutation in 
K14DeltaNLef1 transgenic mice, which inhibits Wnt signalling and prevents 
induction of p53 in skin cancer [76]. In a study in which female mice were treated 
with 7,12-dimethylbenz[a]anthracene, Wnt signalling was up-regulated during 
mammary tumourigenesis [77].  
 
The genes significantly modulated by BaP were analysed with IPA to show their 
regulatory relationships. Most network functions were related to cancer, cell cycle, 
protein synthesis and cellular development, which existed in almost all the organs. 
Interestingly some core genes showed organ-specific patterns, e.g. Ap1, Sp1 and PI3k, 
but the majority of core genes were involved in all organs, including Trp53, NFκb, 
Tnfα, Fos, Stat3, Myc, Ifng and Erbb2. If such pathways are of critical importance it is 
possible that the control of organ specificity of cancer development occurs at a 
different level with different pathways having different roles in different organs. For 
example Cdkn2a is generally involved in cell cycle control but can induce apoptosis 
in lung [78]. 
 
miRNA expression 
miRNAs are small non-coding RNAs of 20-22 nucleotides, typically excised from 60-
110 nucleotide foldback RNA precursor structures [79-82]. They function at 
transcriptional or post-transcriptional levels through imperfect pairing with the target 
mRNA of protein-coding genes. miRNAs are related to crucial biological processes 
including development, differentiation, apoptosis and proliferation [80, 81]. 
 22 
Disregulation of miRNA function is linked to the development of a variety of cancers, 
including breast cancer [83, 84], B-cell leukaemia [85, 86], lung cancer [87, 88] and 
pancreatic cancer [89]. miRNA expression profiling appears in some instances to 
provide a better classification of cancer than conventional expression microarray 
studies [90, 91].  
 
A variety of strategies may be used for miRNA detection, including a bead-based 
flow-cytometric approach [84], quantitative RT-PCR and serial analysis of gene 
expression (SAGE) [92]. In the present study oligonucleotide miRNA microarray 
analysis was used to assess miRNAs expression profiles. The purpose was to 
investigate whether alterations in miRNA profile following PAH exposure provides a 
better indicator of subsequent carcinogenic site-of-action than analysis of overall gene 
expression profile.  
 
When the profiles of altered expression of 54 miRNAs for the 6 organs were analysed 
by hierarchical clustering, the profiles appeared to be tissue specific. Similar results 
have been reported in other studies [84, 92, 93] ; for example, Liu et al. [94] reported 
that 245 miRNAs from humans and mice display tissue-specific expression signatures, 
and Babak et al. [91] found that more than half of 78 detected miRNAs were 
expressed specifically in 17 adult mouse tissues.  
 
An interesting finding was that the magnitudes of the expression differences in the 
deregulated miRNAs were modest. The highest fold-changes were 5.8 for mmu-miR-
298 in colon (up-regulation) and 0.164 for mmu-miR-207 in forestomach (down-
regulation). 60% of the changes were smaller than 2-fold. A study in human breast 
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cancer showed that over 90% of changes were 2-fold or less in 29 deregulated 
miRNAs [83]. Such small changes in human cancers are thought to be significant [85, 
86]. The importance of small changes can be explained if individual miRNAs target 
many genes, and if the small changes can themselves significantly regulate individual 
target genes [92]. It has been shown that oncogenes and/or tumour suppressor genes 
may be disrupted dramatically by modulating miRNAs in human cancers; for example, 
miR-16-1 and miR-15a negatively regulate BCL2 production and miR-17-92 
cooperates with c-Myc to stimulate proliferation [95]. 
 
Only two miRNAs were modulated by more than 2-fold in mouse liver in the present 
study (Table 4). In another study, in which male B6C3F1 mice received 3 daily doses 
of 150 mg/kg b.wt BaP, the maximum fold change in a liver miRNA detected by 
microarray analysis was 1.35, but there were no changes in liver miRNAs that were 
statistically significant [96]. A similar study of miRNA expression changes induced in 
mouse liver by dibenz[a,h]anthracene found that most changes were small (< 1.2 fold) 
and that only one miRNA that showed a dose-dependent increase [97]. Thus although 
miRNA response to environmental mutagens in liver may be a sensitive biomarker for 
liver carcinogens [99], it does not appear to be very sensitive for BaP, for which liver 
is a non-target organ in mice. Yauk and co-workers also found that in mouse lung 13 
miRNAs were significantly modulated following 3 daily doses of 150 or 300 mg/kg 
b.wt BaP [98], but none of these were present in the microarray used in the present 
study (Table 4).  
 
The majority of miRNAs in this study were up-regulated by BaP. In this respect it is 
interesting that miRNA expression levels in tumour samples appears to be globally 
 24 
lower than in normal tissues. For example, 129 of 217 measured mammalian miRNAs 
were down-regulated in multiple human cancers [84]. Calin et al. [92] believe that 
these global miRNA levels facilitate the proliferation and transformation of cells via 
oncogenes genes such as HRAS. On the other hand, miRNAs can down-regulate gene 
expression during various critical cell processes including as apoptosis, differentiation 
and development [93] and negatively regulate target mRNAs [100]. The up-regulation 
of miRNAs in the 6 organs may also be associated with the down-regulation of target 
genes. 
  
mmu-miR-292-5p is predicted to target Erbb2 (miRBase database, 
http://www.mirbase.org/index.shtml). mmu-miR-292-5p was up-regulated in 
forestomach, colon and glandular stomach, and down-regulated in lung. This may 
explain the deregulation of Erbb2 in these organs where Erbb2 was down-regulated in 
forestomach, colon and glandular stomach but up-regulated in lung (see Erbb2 
expression in Table 3). However, confirmation of the interactions of miRNAs and 
genes, such as mmu-miR-292-5p and Erbb2, needs further supporting evidence, e.g. 
confirmation of the modulation of mmu-miR-292-5p by BaP with RT-PCR, 
identification of the mechanism of mmu-miR-292-5p binding to Erbb2, or RNA 
interference to knock-out miRNA functions, as in the studies of miRNAs in 
carcinogenesis [101].  
 
Conclusions 
In an investigation of the early changes induced in mouse organs exposed to a 
carcinogen, we determined whether DNA adduct formation, mRNA or miRNA 
expression can distinguish those mouse organs that are targets for BaP carcinogenesis 
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(lung, spleen, forestomach) from three organs that are non-targets (liver, colon, 
glandular stomach). BaP-DNA adduct levels in mice did not distinguish target from 
non-target organs. miRNA expression patterns were modulated by BaP in a tissue-
specific manner, and to a small extent. Gene expression profiles have provided a 
portrait of the overall tissue-specific expressions of six organs. Two target organs, 
lung and spleen, showed similar gene expression patterns which were different from 
the other four organs. p53 and Stat3 activities may suggest the mechanism that 
distinguishes these two organs. Conversely, there is little to distinguish the responses 
of the forestomach (target) from the glandular stomach (non-target). The modulation 
of Cdh1, Ctnnb1 and Apc indicates Wnt/β-catenin activity specificity in non-target 
organs. Bioinformatic approaches suggest that cell cycle, immune response, MAPK 
signalling and Wnt signalling play critical roles in BaP carcinogenicity. Studies that 
describe carcinogen-induced gene expression differences between a single target 
organ and a single non-target organ should be treated with caution. 
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Materials and methods 
Animal treatment 
Based on published protocols [4], the regimens for BaP treatment in this study are 
predicted to result in significant tumourigenesis in the long-term. 
 
All animal procedures were carried out under licence from the UK Home Office in 
accordance with the Animals (Scientific Procedures) Act 1986, and with the approval 
of the Local Ethics Committee (Institute of Cancer Research). 
 
In Experiment 1, groups of 5 male or female Balb/c mice (6 weeks old, ~25 g each) 
were administered daily doses of 125 mg/kg b.wt/day BaP (96% purity, Sigma-
Aldrich, Poole, UK) (dissolved in 0.2 mL corn oil) by oral gavage. Some groups 
received 5 doses on days 1-5 and were killed on day 8. Others received a further 5 
doses on days 8-12 and were killed on day 15. Control mice received corn oil only.  
 
In Experiment 2, groups of 5 male or female Balb/c mice were administered 5 daily 
doses of 125, 250 or 375 mg/kg b.wt/day BaP on days 1-5 and killed on day 6. 
Control mice received corn oil only. 
 
Six organs (lung, spleen, forestomach, liver, colon and glandular stomach) were 
collected from each mouse, snap-frozen in liquid nitrogen and stored at –80ºC until 
analysis.  
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32P-Postlabelling analysis 
Genomic DNA from the organs of 3 mice per treatment group in Experiment 1 was 
isolated by a standard phenol-chloroform extraction method and DNA adducts were 
measured using the nuclease P1 enrichment version of the 32P-postlabelling method as 
described [10]. Briefly, DNA (4 µg) was digested with micrococcal nuclease and calf 
spleen phosphodiesterase, then with nuclease P1 and 32P-labelled as reported. Solvents 
for 2-D thin-layer chromatography (TLC) of 32P-labelled adducts on 
polyethyleneimine-cellulose were as described [102]. TLC plates were scanned using 
a Packard Instant Imager (Dowers Grove, IL, USA) and DNA adduct levels were 
calculated from the adduct cpm and the specific activity of [γ-32P]ATP and expressed 
as adducts per 108 nucleotides. An external BPDE-DNA standard [103] was employed 
for identification of adducts in experimental samples.  
 
cDNA microarray  
Total RNA from the 6 organs treated in Experiment 2 was extracted by Trizol reagent 
(Invitrogen, Paisley, UK) and purified by Qiagen RNeasy mini kit (Qiagen, Crawley, 
UK) according to the manufacturer’s instructions. RNA was quantified 
spectrophotometrically, and integrity was determined using a 2100 BioAnalyzer 
(Agilent Technologies, South Queensferry, UK). RNA that had an rRNA 28S/18S 
ratio >1.2 was used.  
 
Total RNA (4 µg) was reverse transcribed into cDNA and labelled with Cy5 dye (GE 
Healthcare, Chalfont St Giles, UK) using the Invitrogen indirect cDNA labelling kit 
protocol (Invitrogen) according to the manufacturer’s instructions. Four µg of 
universal mouse reference RNA (UMRR) (Stratagene, La Jolla, CA, USA) was 
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labelled with Cy3 dye (GE Healthcare). After labelling, repetitive sequences within 
the cDNA samples were blocked with 10 µg mouse Cot-1 DNA (Invitrogen) to 
prevent non-specific sequences binding to the cDNA probes. Cy5-labelled test and 
Cy3-labelled reference were co-hybridised onto custom cDNA mouse microarrays 
containing 13,825 features (NIA 15K Mouse cDNA clone set) [104]. Three total RNA 
samples from 3 mice were hybridised with UMRR. Slides were incubated at 42°C for 
16 hours. Washes were performed once in 2× SSC and 0.1% (w/v) SDS for 15 min, 
followed by three washes in 0.1 × SSC and 0.1% (weight/vol) SDS for 10 min each, 
and two final washes in 0.1 × SSC for 2 min each, all at 65°C. Slides were spin dried 
before scanning on an Axon 4000A laser scanner (Axon Instruments, Union City, CA, 
USA) according to the manufacturer’s protocol. 
 
Microarray data preparation 
The initial quality analysis of the scanned slides was carried out using GenePix Pro v-
5.1 (Axon Instruments). A spot was automatically flagged for inclusion if the signal 
intensity of >75% of the pixels from either the Cy3 or Cy5 channels was 1 S.D. above 
background intensity. Spot quality was also assessed visually to fine tune the flagging. 
Raw data from GenePix were imported into GeneSpring v-7.2 (Agilent Technologies) 
without background subtraction and LOWESS normalisation [105] was applied. 
Natural log transformed averaged Cy5/Cy3 ratios were used in all subsequent 
analyses. PCA and HCA were performed on significantly modulated genes. The gene 
expression data discussed in this publication have been deposited in EMBL-EBI 
arrayExpress (https://www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-
80.  
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Pathway analysis 
All genes modulated significantly by BaP in each organ were included for these 
analyses. Gene ontology (GO) [106] was performed by Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [107]. In this study we concentrated 
on the significant (p < 0.05) biological processes. A second approach concentrated on 
gene interaction and cascade mechanisms like signalling transduction. The signalling 
annotation from pathway collections, including Biocarta, GenMAPP and KEGG were 
carried out using Pathway Miner [108]. Thirdly, gene association network (GAN) 
analysis, which examines all classes of relationships between genes, was carried out 
using Ingenuity pathway analysis (IPA) (Ingenuity systems, Redwood City, CA, 
USA). 
 
Taqman gene expression assay 
cDNA was reversed transcribed from 1 µg total RNA (comprising equal amounts 
from 3 mice/group from Experiment 2) using random primers following the 
superscript III Reverse transcriptase first-strand cDNA synthesis protocol 
(Invitrogen). The cDNA was diluted 1:10 to 200 µL and 2 µL was used as template to 
perform Real-Time PCR in a 15-µl reaction. GAPDH was used as an endogenous 
control (Applied Biosystems, Foster City, CA, USA) in multiplexed PCR reactions on 
an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) with 
standard thermocycling conditions (50°C for 2 min, 95°C for 10 min, then 40 cycles 
at 95°C for 15 s, 60°C for 1 min), using Taqman Universal PCR Master Mix (Applied 
Biosystems). To confirm the modulated expression of the selected genes 20× Assays-
On-Demand™ gene expression primers and probes (Applied Biosystems) were used.  
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The assay codes were: GAPDH-4352339E, Trp53-Mm00441964_g1, Pcna-
Mm00448100_g1, Ccng1-Mm00438084_m1, Ephx1-Mm00468752_m1, Cyp1a1-
Mm00487218_m1, Cdh1-Mm00486906_m1, Ctnnb1-Mm01350394_m1, Apc-
Mm00545877_m1, Stat3-Mm00456961_m1, Erbb2-Mm00658541_m1, Src-
Mm00436783_m1, Hspa8-Mm01731394_gH, Hspa5-Mm00517691_m1, Fos-
Mm00487425_m1, Myc-Mm00487804_m1, NFκB-Mm00476361_m1, Tnfα-
Mm00443258_m1, Cav-Mm00483057_m1, Tubb5-Mm00495804_m1, Cdkn2a-
Mm00494449_m1, Ccnd2-Mm00438071_m1. 
 
PCR reactions were performed in triplicate and changes in gene expression between 
the control (calibrator) and treated samples after normalisation to the GAPDH 
reference were calculated using the comparative threshold cycle (CT) method, where 
relative amount = 2-∆∆CT and ∆∆CT is the ∆CT of the target gene (threshold cycle test 
gene - threshold cycle endogenous control) minus the ∆CT of the calibrator sample 
(threshold cycle calibrator gene - threshold cycle endogenous control).  
 
MicroRNA 
The 6 organs from 2 female BaP-treated (125 mg/kg/day for 5 days) and 2 corn oil-
treated mice from Experiment 2 were used for analysis of miRNA expression. 
Supernatants containing total RNA, prepared as described above, were transferred to 
columns in miracle miRNA isolation kit (Stratagene, La Jolla, CA, USA) and miRNA 
isolated according to the manufacturer’s instructions. Samples were stored at –80oC 
until analysis. 
The miRCURY LNA miRNA array (Exiqon, Vedback, Denmark; kindly provided by 
Dr Eduardo Missiaglia, Institute of Cancer Research; http://www.exiqon.com/array), 
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which contains 54 mouse miRNAs, was used: 0.1 µg miRNA from BaP-treated mice 
was mixed with 8 µL 2.5× labelling buffer, 1.4 µL Cy5 fluorescent dye, 0.7 µL 
positive control, 14. µL labelling enzyme and the final volume adjusted to 20 µL with 
nuclease-free water. Another 0.1 µg miRNA from corn oil-treated mice was mixed 
with the same reagents, except for Cy3 instead of Cy5. Incubation was at 0oC for 1 
hour, then at 65oC for 15 min to stop the labelling, after which the mixtures were 
concentrated to 7.5 µL and placed on ice. 
The two mixtures were pooled and 5 µL 4× hybridisation buffer (GE Healthcare, 
Amersham, UK) was added. The solution was heated at 95oC for 3 min, centrifuged 
briefly, then applied to the arrays on a heating block at 63oC for 5 min, then covered 
with a glass cover slip and incubated at 63oC for 24 hours in a hybridisation chamber. 
Then the arrays were washed with solution A (20 mL 20x SSC, 4 mL 10% SDS, 176 
mL HLPC-pure water) for less than 1 min at 60oC, followed by solution B (10 mL 
20x SSC, 190 mL HPLC-pure water) twice for 2 min at room temperature, followed 
by solution C (2 mL 20x SSC, 198 mL HPLC-pure water) for 2 min at room 
temperature, and finally briefly with HPLC-pure water, then dried under a stream of 
air. 
Scanning and image processing of the arrays was the same as for cDNA microarrays. 
The data were loaded into Genespring without background subtraction and normalised 
(per spot method), and modulated miRNAs identified by the fold-change method. 
Comparisons between the 6 organs were performed in Microsoft Office Excel. The 
miRNA expression data have been deposited in EMBL-EBI arrayExpress 
(https://www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-2407. 
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Statistical analysis 
For DNA adducts, comparisons between males and females and between 5-day and 
10-day exposures were carried out using Student’s t-test (2-tailed). DNA adduct levels 
in 6 organs were tested by 1-way ANOVA and the Tukey-Kramer Test was used to 
identify significant differences (p < 0.05) between pairs of organs. For cDNA 
microarray data analyses, the significantly modulated genes were tested using 
Welch’s t-tests between test and control samples with test parameter non-adjusted p < 
0.05. Two-way ANOVA was used to test for significant differences between males 
and females, as well as between the three levels of dosage with BaP. For HCA, 
Pearson’s correlation was used to calculate the distances with a Euclidean inter-group 
distance. For gene functional analysis, Fisher’s exact test was applied in gene 
ontology and pathway analyses. Pearson’s correlation was employed in analysing 
expression relationships between microarray and Taqman assay results. For RT-PCR 
data analyses, the differential expression was tested using Welch’s t-test with the 
Benjamin-Hochberg multiple testing correction. For the miRNA analyses, one-way 
ANOVA was used to test for significant differences between treated and control 
tissues. 
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Availability of Supporting Data 
The gene expression data have been deposited in EMBL-EBI arrayExpress 
(https://www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-80.  
The miRNA expression data have been deposited in EMBL-EBI arrayExpress 
(https://www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-2407. 
Supplementary Tables 1-6 are appended. 
 
Abbreviations: BaP, benzo[a]pyrene; BPDE, benzo[a]pyrene diol-epoxide; ANOVA, 
analysis of variance; PCA, principal component analysis; HCA, hierarchical cluster 
analysis; GAN, gene association network; GO, gene ontology; miRNA, microRNA. 
IPA, Ingenuity Pathway Analysis; IQR, interquartile range. 
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Legends to figures 
 
Figure 1. BaP–DNA adduct formation in 6 Balb/c mouse organs. The mice received 5 
or 10 daily doses of 125 mg/kg b.wt/day BaP, or corn oil (control). (A) 
Autoradiographic profiles of DNA adducts obtained by TLC-32P-postlabelling. (B) 
Quantitative analysis of DNA adducts in mouse organs. Values represent the 
mean ± SD (n = 3). RAL; relative adduct labelling, adducts/108 nucleotides. 
Differences between males and females were not significant (p>0.05). Differences 
between 5 and 10 days were significant (p<0.05) except for lung (p=0.06) 
 
Figure 2. (A) Principal component analysis (PCA) of 2791 genes modulated 
significantly by BaP across 6 mouse organs. The first and second components were 
used (75.31% of total variances). The 8 hybridisation conditions in each of the 6 
organs were grouped by gender and BaP dose (males or females, BaP dose of 125, 
250 or 375 mg/kg b.wt/day and corn oil). T indicates target organs and NT non-target 
organs. (B) Hierarchical clustering analysis (HCA) of 2741 genes modulated 
significantly by BaP across 6 mouse organs. The 48 hybridisation conditions were 
clustered unsupervised. The results show tissue-specific expression patterns, 
especially in 2 target organs (lung and spleen). dose 1-corn oil, dose 2-BaP 125 mg/kg 
b.wt/day, dose 3-BaP 250 mg/kg b.wt/day, dose 4-BaP 375 mg/kg b.wt/day. LU-lung, 
SP-spleen, FS-forestomach, LI-liver, CO-colon, GS-glandular stomach. 
 
Figure 3. Gene association network (GAN) 3 in lung. The network was generated 
with 791 BaP-significantly modulated genes by Ingenuity Pathway Analysis (IPA). 
(A) shows 28 BaP-modulated genes. The gene-gene interactions reveal that NFκb can 
be regulated by 10 genes (Ecsit, Gpam, Ddost, Cops3, Birc4, Otud7b, Nedd4, Ube2, 
Btrc and Rnf7) and it may regulate other 3 genes (Fuca1, Cyb5r3 and Ccnd2). It also 
shows that core genes NFκb and Ube give central roles for the network functions 
protein synthesis and post-translational modification. Up-regulated genes are shown 
in red; down-regulated genes are shown in green (B) The descriptions of interactions 
and transcriptional factors. 
 
Figure 4. Boxplots of the eight genes found to be modulated significantly differently 
between target and non-target organs (p < 0.05; Benjamin-Hochberg multiple testing 
correction applied). Expression values were normalised to the corn-oil control for 
each organ and pooled according to target or non-target status. Each organ is 
identified by colour. The box indicates the median, upper and lower quartiles and the 
whiskers are 1.5 times IQR (interquartile range; Q3-Q1) above/below the box. 
 
Figure 5. Hierarchical cluster analysis (HCA) of 54 mouse miRNAs in 6 mouse 
organs. The female mice received 5 daily doses of 125 mg/kg b.wt/day of BaP by oral 
gavage. 6 organs were unsupervised clustered with Pearson’s correlation analysis. The 
results show tissue specific expression patterns (LU-lung, LI-liver, SP-spleen, CO-
colon, GS-glandular stomach, FS-forestomach). 
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Legends to tables 
 
Table 1. Genes significantly modulated by BaP in individual organs (Welch’s t-test, p 
< 0.05) for at least three conditions. Columns M1, M2, M3, F1, F2 and F3 show the 
relative fold-change values in 6 exposure conditions (M1-male 125, M2-male 250, 
M3-male 375, F1-female 125, F2-female 250 and F3-female 375 mg/kg/day. 
Expression in bold means being significant (p <0.05) by Welch's t-test. The 
expression of those genes underlined were subsequently validated by Taqman gene 
expression assay. 
 
Table 2. Genes found to be significantly differentially expressed (Welch t-test p < 
0.05) in the same direction for all target organs or all non-target organs. In the 
analysis samples were grouped by organ. Ratios are only displayed for those organs 
where a significant difference was found. LU = lung; SP = spleen; FS = forestomach; 
LI = liver; CO = colon; GS = glandular stomach. 
 
Table 3. Gene expression changes validation with Real-Time PCR. The same RNA 
sample was measured 3 times independently for each exposure condition, and the 
consistent changes with a cut-off 1.5 occurring in 3 or more conditions in each organ 
was considered as being up- or down-regulated.  means up-regulation;  
means down-regulation; ‘ – ’ means no change and ‘F’ means no data. 
 
Table 4. The 21 miRNAs significantly modulated in 6 female mouse organs. The 
mice received 5 daily doses of 125 mg/kg b.wt/day of BaP by oral gavage. The 
numbers represent fold change in expression relative to control organs (red, up-
regulated; green, down-regulated). The deregulated miRNAs were filtered by relative 
expression ratios with fold-change cut-offs of 1.5 (t-test p<0.05). 
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Table 1. Genes significantly modulated by BaP in individual organs (Welch’s t-test, p 
< 0.05) for at least three conditions. Columns M1, M2, M3, F1, F2 and F3 show the 
relative fold-change values in 6 exposure conditions (M1-male 125, M2-male 250, 
M3-male 375, F1-female 125, F2-female 250 and F3-female 375 mg/kg b.wt/day. 
Expression in bold means being significant (p < 0.05) by Welch's t-test. The 
expression of those genes underlined were subsequently validated by Taqman gene 
expression assay. 
 
Probe Symbol Gene name EntrezID M1* M2 M3 F1 F2 F3 
lung 
(target) 
         
H3018D10 Actb actin, beta, cytoplasmic 11461 1.310 1.280 1.290 1.020 1.010 1.080 
H3089D06 Cav caveolae protein 1 12389 2.350 2.270 2.260 1.500 1.730 1.660 
H3110F10 Ephx1 epoxide hydrolase 1, microsomal 13849 1.424 1.696 1.658 2.220 2.382 2.910 
H3114C04 Giyd2 giy-yig domain containing 2 75764 0.530 0.800 0.610 0.430 0.410 0.600 
H3125H11 Hba-a1 hemoglobin alpha, adult chain 1 15122 0.597 0.687 0.487 0.502 0.442 0.580 
H3117D02 Hbb-y hemoglobin y, beta-like embryonic chain 15135 0.445 0.732 0.356 0.369 0.217 0.405 
H3139E01 Hspa8 heat shock protein 8 15481 1.687 2.068 1.994 2.060 1.954 1.625 
H3097B08 Pdia3 protein disulfide isomerase associated 3 14827 1.211 1.283 1.388 1.270 1.126 1.232 
H3126C02 Rpl18 ribosomal protein l18 19899 1.350 1.400 1.490 1.040 1.010 0.980 
H3112G04 Rps5 ribosomal protein s5 20103 1.310 1.290 1.350 0.970 0.860 1.000 
H3068A11 Tmed5 
transmembrane emp24 protein transport domain 
containing 5 
73130 1.270 1.310 1.330 1.320 1.120 1.270 
spleen (target)         
H3077H03 Ccng1 cyclin g1 12450 1.342 1.362 1.665 1.359   1.564 
H3114C04 Giyd2 giy-yig domain containing 2 75764 0.443 0.393 0.513 0.484 0.203 0.383 
H3126A10 Hba-a1 hemoglobin alpha, adult chain 1 15122 0.540 0.661 0.581 0.358 0.327 0.335 
H3134E01 Hbb-y hemoglobin y, beta-like embryonic chain 15135 0.813 0.742 0.495 0.542 0.334 0.564 
H3051C06 Hspa5 heat shock 70kd protein 5 14828 1.061 1.359 1.433 1.047 1.241 1.522 
H3139E01 Hspa8 heat shock protein 8 15481 1.297 1.540 1.567 1.937 1.784 1.705 
H3097B08 Pdia3 protein disulfide isomerase associated 3 14827 1.126 1.224 1.388 1.161 1.204 1.425 
H3130D03 Pip5k1c 
phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma 
18717 0.330 0.340 0.420 0.640 0.470 0.530 
H3139D02 Tubb5 tubulin, beta 5 22154 0.649 0.650 0.716 0.744 0.619 0.725 
forestomach (target)         
H3011E09 Actb actin, beta, cytoplasmic 11461 1.210 1.860 1.930 1.670 1.520 1.950 
H3089D06 Cav caveolae protein 1 12389 
 
0.570 0.630 0.570 0.910 0.700 
H3126H01 Hba-a1 hemoglobin alpha, adult chain 1 15122 0.210 0.240 0.150 0.510 0.470 0.300 
H3051C06 Hspa5 heat shock 70kd protein 5 14828 1.332 1.837 2.287 1.716 1.687 1.803 
H3139E01 Hspa8 heat shock protein 8 15481 1.570 2.382 2.752 1.674 1.956 2.153 
H3130D03 Pip5k1c 
phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma 
18717 0.520 0.550 0.740 0.590 0.560 0.790 
H3126C02 Rpl18 ribosomal protein l18 19899 1.510 1.370 1.640 0.950 1.030 1.160 
H3112G02 Rps5 ribosomal protein s5 20103 1.320 1.270 1.440 1.040 1.050 1.360 
H3080H08 Tmed5 
transmembrane emp24 protein transport domain 
containing 5 
73130 0.660 0.690 0.720 0.610 0.580 0.530 
H3018E11 Tubb5 tubulin, beta 5 22154 0.588 0.624 0.576 1.117 1.115 1.098 
liver (non-target)         
H3133B06 Ccnd2 cyclin d2 12444 1.757 2.639 1.519 1.724 1.532 1.924 
H3125H11 Hba-a1 hemoglobin alpha, adult chain 1 15122 0.170 0.420 0.490 0.490 0.280 0.290 
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H3139E01 Hspa8 heat shock protein 8 15481 0.935 1.592 1.354 1.870 2.606 2.456 
H3129E07 Rpl17 ribosomal protein l17 319195 1.130 1.320 1.200 1.220 1.370 2.050 
colon (non-target)         
H3139E01 Hspa8 heat shock protein 8 15481 1.397 1.493 1.559 1.240 1.577 2.110 
H3139D02 Tubb5 tubulin, beta 5 22154 1.951 2.106 2.216 1.318 1.717 1.749 
glandular stomach (non-target)        
H3089D06 Cav caveolae protein 1 12389       2.140 1.530 1.300 
H3126H01 Hba-a1 hemoglobin alpha, adult chain 1 15122 0.610 0.340 0.310 0.310 0.250 0.240 
H3051C06 Hspa5 heat shock 70kd protein 5 14828 1.316 1.780 1.294 1.253 1.661 1.165 
H3029C06 Hspa8 heat shock protein 8 15481 1.242 1.303 1.046 1.568 1.480 1.266 
H3029F12 Rpl17 ribosomal protein l17 319195 1.340 1.350 1.020 1.400 1.400 2.130 
*Expression in bold means being significant (p<0.05) by Welch's t-test 
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Table 2. Genes found to be significantly differentially expressed (Welch t-test p < 
0.05) in the same direction for all target organs or all non-target organs. In the 
analysis samples were grouped by organ. All three doses are included. Ratios are only 
displayed for those organs where a significant difference was found. LU = lung; SP = 
spleen; FS = forestomach; LI = liver; CO = colon; GS = glandular stomach. 
 
Clone ID Symbol Gene Name EntrezID Genbank LU SP FS LI CO GS
H3098H09 2310016E02Rik riken cdna 2310016e02 gene 67695 BG071432 1.44 1.19 2.19 1.31 0.65 -
H3114E08 Actg1 actin, gamma, cytoplasmic 1 11465 BG072752 1.20 1.17 1.27 - - -
H3134D01 AI461788 BG074374 1.53 1.28 1.41 2.02 - -
H3083A04 Crk V-crk sarcoma virus CT10 oncogene 
homolog (avian)
12928 BG069956 1.19 1.11 1.24 - - -
H3094A04 Dnajc3 DnaJ (Hsp40) homolog, subfamily C, 
member 3
100037258 BG071035 1.20 1.26 1.42 - - 0.90
H3134F05 Gstm1 Glutathione S-transferase, mu 1 14862 BG074397 2.29 1.43 1.46 2.26 - -
H3125H07 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG073608 0.59 0.54 0.57 0.26 - 0.42
H3125H08 Hba-a1 Hemoglobin alpha, adult chain 1 15122 CK334953 0.58 0.70 - 0.32 0.95 0.50
H3125H11 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG073610 0.54 0.77 0.40 0.35 - 0.37
H3126G09 Hba-a1 Hemoglobin alpha, adult chain 1 15122 CK334957 0.55 0.42 0.33 0.35 - 0.35
H3126H01 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG073679 0.58 0.44 0.28 0.25 2.02 0.32
H3140G04 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG074904 0.52 0.73 0.49 0.29 - 0.49
H3117D02 Hbb-y hemoglobin Y, beta-like embryonic 
chain
15135 BG072990 0.39 - 0.45 0.23 0.95 0.44
H3134E01 Hbb-y hemoglobin Y, beta-like embryonic 
chain
15135 CK335036 0.51 0.56 0.43 0.31 1.19 0.43
H3051C06 Hspa5 Heat shock protein 5 14828 CK334553 1.37 1.26 1.76 - 1.02 1.40
H3012A07 Hspa8 Heat shock protein 8 15481 BG063725 1.78 1.33 1.73 1.69 - -
H3119B04 Hspa8 Heat shock protein 8 15481 CK334899 1.79 1.36 1.62 1.46 0.93 -
H3139E01 Hspa8 Heat shock protein 8 15481 BG074803 1.89 1.61 2.04 1.70 0.75 -
H3058G09 Mod1 Malic enzyme 1, NADP(+)-dependent, 
cytosolic
17436 BG067842 1.74 1.37 1.39 1.57 - 1.26
H3012G01 Pfpl Pore forming protein-like 56093 CK334280 - - - 1.21 1.08 1.21
H3032C09 Psmd2 Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 2
21762 BG065537 0.87 0.89 0.84 - 1.50 -
H3082D02 Sdccag1 serologically defined colon cancer 
antigen 1
71055 BG070064 1.59 1.58 1.53 1.52 1.05 1.46
H3106H07 Slco2a1 Solute carrier organic anion transporter 
family, member 2a1
24059 BG072114 1.46 1.22 1.32 - - 1.19
H3068A11 Tecpr1 Tectonin beta-propeller repeat 
containing 1
70381 BG068669 1.27 1.19 2.00 - 0.68 -
H3131D02 Tnk2 Tyrosine kinase, non-receptor, 2 51789 BG074141 - 0.85 - 0.78 0.71 0.56
H3098D07 1.12 1.10 1.31 - - -
H3114F08 1.11 1.29 1.10 - - 1.24
Average ratio of BaP-treated 
samples to oil treated control
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Table 3. Gene expression changes validation with RT-PCR. The same RNA sample 
was measured 3 times independently for each exposure condition, and the consistent 
changes with a cut-off 1.5 occurring in 3 or more conditions in each organ was 
considered as being up- or down-regulated.  means up-regulation;  
means down-regulation; ‘ – ’ means no change and ‘F’ means no data. 
 
Symbol EntrezID Gene Name LU* SP FS LI CO GS
P53 related
Trp53 22059  transformation related protein 53 ↓ ↓ F F F F
Pcna 18538  proliferating cell nuclear antigen ↓ ↓ − − − −
Ccng1 12450  Cyclin G1 ↑ ↑ ↑ ↑ ↑ ↑
PAH metabolism
Ephx1 13849  epoxide hydrolase 1, microsomal ↑ ↑ − ↑ ↑ ↑
Cyp1a1 13076  cytochrome P450, family 1, subfamily a, polypeptide 1 ↑ ↑ ↑ ↑ ↑ ↑
Wnt/β-catenin signalling
Cdh1 12550  Cadherin 1 − ↑ − ↓ ↓ ↓
Ctnnb1 12387  catenin − − − − ↓ ↓
Apc 11789  adenomatosis polyposis coli − − − − ↓ ↓
Stat3 related
Stat 3 20848  signal transducer and activator of transcription 3 − ↑ ↑ ↑ ↑ ↑
Erbb2 13866  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 ↑ F ↓ F ↓ ↓
Src 20779  Rous sarcoma oncogene ↑ ↑ − F − −
Oncogene and tumour suppressor gene
Fos 14281  FBJ osteosarcoma oncogene ↓ ↑ ↑ ↓ ↓ ↓
Myc 17869  myelocytomatosis oncogene ↓ − − ↑ − ↑
Other genes
Cav 12389 caveolin, caveolae protein 1 ↑ ↑ ↓ ↑ − ↑
Tubb5 22154 tubulin, beta 5 ↓ ↓ − − − −
Cdkn2a 12578 cyclin-dependent kinase inhibitor 2A (P16) − ↑ ↑ ↑ F ↑
Ccnd2 12444 Cyclin D2 − ↑ ↓ ↑ ↑ −
Hspa8 15481  heat shock 70kD protein 8 ↑ ↑ ↑ ↑ ↑ ↑
Hspa5 14828  heat shock 70kD protein 5 ↑ − ↑ − ↑ ↑
TNFα 21926  tumor necrosis factor alpha ↓ − F F ↑ F
NFκb 18033  nuclear factor of kappa light chain gene enhancer in B-cells 1 ↓ − F F ↓ F
* Organs LU-lung, SP-spleen, FS-forestomach, LI-liver, CO-colon, GS-glandular stomach.
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Table 4. The 21 miRNAs significantly modulated in 6 female mouse organs. The 
mice received 5 daily doses of 125 mg/kg b.wt/day of BaP by oral gavage. The 
numbers represent fold change in expression relative to control organs (red, up-
regulated; green, down-regulated). The deregulated miRNAs were filtered by relative 
expression ratios with fold-change cut-offs of 1.5 (t-test p < 0.05). 
 
miRNA lung spleen forestom
ach
liver colon glandular 
stomach
1 mmu-miR-140* 0.45 1.54
2 mmu-miR-199b 0.35
3 mmu-miR-207 1.58 1.81 0.16 1.70 2.44
4 mmu-miR-290 1.50 2.03 1.50 3.40 1.86
5 mmu-miR-291a-3p 1.70 1.85
6 mmu-miR-291a-5p 1.55
7 mmu-miR-291b-5p 0.65 2.33 2.64 3.11 1.86
8 mmu-miR-292-3p 0.58
9 mmu-miR-292-5p 0.59 1.87 3.24 4.10 1.57
10 mmu-miR-298 2.55 2.27 5.81 1.86
11 mmu-miR-346 2.01 2.35 1.57 1.72
12 mmu-miR-351 1.63 7.24 2.15 1.95
13 mmu-miR-376b 1.95 1.86 2.27
14 mmu-miR-433-5p 0.63 0.53 0.57 1.85 3.57
15 mmu-miR-434-3p 1.70 0.65
16 mmu-miR-464 0.32
17 mmu-miR-483 1.84
18 mmu-miR-489 2.19 0.30 2.13
19 mmu-miR-503 1.52 2.02 1.65
20 mmu-miR-542-5p 1.79
21 mmu-miR-546 2.74 0.61 1.99
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